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Abstract
Background: Coxsackievirus B3 is an important infectious agent of viral myocarditis, pancreatitis and aseptic
meningitis, but there are no specific antiviral therapeutic reagents in clinical use. RNA interference-based
technology has been developed to prevent the viral infection.
Methods: To evaluate the impact of RNA interference on viral replication, cytopathogenicity and animal survival,
short hairpin RNAs targeting the viral 2B region (shRNA-2B) expressed by a recombinant vector (pGCL-2B) or a
recombinant lentivirus (Lenti-2B) were tansfected in HeLa cells or transduced in mice infected with CVB3.
Results: ShRNA-2B exhibited a significant effect on inhibition of viral production in HeLa cells. Furthermore,
shRNA-2B improved mouse survival rate, reduced the viral tissues titers and attenuated tissue damage compared
with those of the shRNA-NC treated control group. Lenti-2B displayed more effective role in inhibition of viral
replication than pGCL-2B in vivo.
Conclusions: Coxsackievirus B3 2B is an effective target of gene silencing against coxsackievirus B3 infection,
suggesting that shRNA-2B is a potential agent for further development into a treatment for enterviral diseases.
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Background
Coxsackievirus B3 (CVB3) is among the most common
and significant causative agents of heart muscle disease
in human. CVB3 is a member of the genus Enterovirus,
which belongs to the family Picornaviridae. The
spectrum of disease caused by these viruses ranges from
very mild to life-threatening [1]. In some cases, CVB3
may escape the intestinal tract to produce serious dis-
eases, such as viral myocarditis [2], pancreatitis [3] and
aseptic meningitis [4]. It is estimated that at least 50% of
the cases of infection-caused heart diseases are attribut-
able to CVB3 infection [5]. However, there is currently
no available vaccine and no specific drug to eliminate
virus infection.
The CVB3 genome is a single-stranded positive-sense
RNA molecule of approximately 7.4 kb. It contains a 5’-
untranslated region (5’-UTR), a single long open reading
frame, 3’-UTR, and a poly(A) tail. The four capsid pro-
teins (VP1-4) and seven nonstructural proteins (2A, 2B,
2C, 3A, 3B, 3C, 3D) are generated by viral protease-
mediated process of the single polyprotein translated
from the genomic RNA [6]. CVB3 replication induces a
direct cytopathic effect (CPE) on infected cells and dir-
ect tissue damage in various animal models [7,8]. There-
fore, it is considered that virus elimination at a specific
target can be the key therapeutic strategy to treat or at-
tenuate CVB3-related disease.
RNA interference (RNAi) is a mechanism that inhibits
specific gene expression by using short double-stranded
RNA (dsRNA), which is converted to small interfering
RNA (siRNA) as the active agent. RNAi is now
employed as a potential therapeutic method against
pathogenic viruses [9,10]. It is reported that several
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human pathogens, including human immunodeficiency
virus [11], the hepatitis B [12] and C [13] viruses, influ-
enza A virus [14] and coxsackievirus [15], were inhibited
or eliminated by RNAi.
In our previous study, we designed twelve siRNAs tar-
geting distinct regions of the CVB3 genome, and investi-
gated their antiviral activities in HeLa cell [16]. The
most effective one is siRNA-2B, targeting viral RNA at
2B region (3753-3771), achieving a 90% reduction of
CVB3 replication [17]. In this study, we developed a re-
combinant plasmid and a lentivirus vector that delivered
the short hairpin RNAs (shRNAs) targeting 2B gene
(3753-3771) in cell culture system and in an animal
model to evaluate the impact of shRNA-2B on CVB3
replication, pathogenicity and survival in vitro and
in vivo.
Methods
Cell culture, virus, transfection and infection
HeLa and 293T cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum, 100 units/ml penicillin, and
100 μg/ml streptomycin. CVB3M strain was amplified in
HeLa cells by infection. This strain was a kind gift from
Dr S.A. Huber, University of Vermont, U.S.A. [18]. To
assess the validity of shRNA-2B, HeLa cells were seeded
into 12-well plates (1 × 105 cells/well) overnight. When
reached 50-60% confluency, cells were washed with
phosphate buffered saline (PBS) and transfected with
plasmid or transduced with lentivirus. At 24 h post
transfection or 48 h post transduction, cells were washed
and infected with CVB3 (MOI = 0.01) for 1 h. The cells
were then overlaid with complete medium and incu-
bated at 37°C with 5% CO2. At different time points post
infection, supernatants were collected to determine the
virus titers by viral plaque assay. Experiments were car-
ried out 3 times.
Recombinant plasmid and lentivirus generation
pHelper 1.0, pHelper 2.0 and pGCSIL-GFP plasmids
were purchased from Shanghai GeneChem Co. Ltd.
(Shanghai, China). To construct the recombinant vector,
RNAi stem-loop DNA oligos containing the target
sequences (GGACTATGTGGAACAGCTT) in the re-
gion of CVB3 2B were chemically synthesized, annealed
and cloned into the AgeI/EcoRI-digested pGCSIL-GFP,
thus generating the plasmid pGCL-2B. The lentiviral
vector pGCSIL-GFP contained a U6 promoter to express
continuously the shRNA and CMV promoter to express
the green fluorescent protein (GFP), which could be
used to detect the transfection efficiency of viral pack-
aging and infection. Recombinant lentiviruses were gen-
erated by co-transfection of 293T cells with 20 μg
pGCL-2B and packaging vectors (15 μg pHelper1.0,
10 μg pHelper2.0) using 100 μl of Lipofectamine 2000™
reagent according to the manufacturer’s instructions
(Invitrogen, USA). The recombinant lentivirus was
designated Lenti-2B. The viral supernatant was har-
vested 48 h after transfection, passed through 0.45 μm
filters and concentrated. The viral titer was determined
by infecting 293T cells with serial dilutions of concen-
trated lentivirus, and then determining the GFP expres-
sion of infected cells by fluorescence microscopy 96 h
after infection. Therefore, the titer is expressed as
“transduction unit (TU)/ml”. A scramble siRNA se-
quence (5’-UUCUCCGAACGUGUCACGU-3’) was used
to generate the non-silence control plasmid and lenti-
virus that were designated pGCL-NC and Lenti-NC.
Short hairpin RNAs treatment in vivo
6-week-old BALB/c male mice were injected via caudal
vein with plasmid or lentivirus. Entranster™-in vivo trans-
fection reagent (Engreen Biosystem Co, Ltd. China) was
used to deliver the plasmids. Control mice were injected
with pGCL-NC, Lenti-NC and minimum essential
medium (MEM), respectively. After 24 h, all mice were
inoculated intraperitoneally with a dose of 8 × 103 plaque-
forming units (pfu)/mouse of CVB3 virus. Some mice
were observed for survival time. Other mice were eutha-
nized on days 3, 5 and 7 after infected with CVB3 (n= 10
per group). Experiments were carried out 3 times. The
animal experiment has been performed with the approval
of the ethics committee of Capital Institute of Pediatrics
and followed internationally recognized guidelines.
Organ virus titers and histological analysis
Hearts and pancreases from mice were weighted, homo-
genized in 0.5 ml MEM, and centrifuged for 10 minutes
at 1000 rpm. In the supernatants, infectious virus was
analyzed by viral plaque assay, and the viral titer in
infected tissue was expressed as pfu/g. To assess severity
of myocarditis and pancreatitis, paraffin-embedded sec-
tions of tissues were stained with hematoxylin-eosin and
examined histopathologically for evidence of inflamma-
tion and necrosis. The immunohistochemistry staining
for CVB3 and GFP were performed using anti-
coxsackievirus B3 monoclonal antibody (Chemicon
International, USA) and anti-GFP monoclonal antibody
(Chemicon International, USA) as the primary antibody
following the procedure described previously [19].
Viral plaque assay
HeLa cells were seeded into six-well plates (4× 105 cells/
well) and incubated at 37°C with 5% CO2 for 48 h. When
cell confluency reached approximately 90%, cells were
washed with PBS to remove the fetal bovine serum and
then overlaid with 200 μl of 1:10 diluted supernatant. The
cells were incubated at 37°C for 60 min and the
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Figure 1 Evaluation of the antiviral effects of pGCL-2B in HeLa cells. A HeLa cells were pretreated with pGCL-2B at series of doses and the
percent of GFP-expressing cells were counted through fluorescence microscopy after 24 h. The results of three independent experiments are
expressed as mean ± standard deviation. B HeLa cells were transfected with pGCL-2B (1.25 μg/well), and the transfection rates were counted at
different time points. The results of three independent experiments are expressed as mean ± standard deviation. C HeLa cells were transfected
with pGCL-2B (1.25 μg/well) or pGCL-NC or MEM only (V), followed by CVB3 infection (MOI = 0.01). The viral titers were measured at 36, 48, 60,
72 h p.i. using supernatants of cell cultures by plaque-forming analysis and the results of three independent experiments are expressed as mean
± standard deviation. Significant differences between pGCL-2B treated (white bars) and pGCL-NC treated samples (striped bars) are indicated
(*: P< 0.05) D HeLa cells were transfected with pGCL-2B at 0.75, 1.25 or 1.75 μg/well, respectively, or pGCL-NC or MEM only (V), followed by CVB3
infection (MOI = 0.01). The viral titers were measured at 48 h p.i. using supernatants of cell cultures by plaque-forming analysis and the results of
three independent experiments are expressed as mean ± standard deviation. Significant differences between pGCL-2B treated (white bars) and
pGCL-NC treated samples (striped bars) are indicated (*: P<0.05) E HeLa cells were transfected with pGCL-2B (1.25 μg/well) or pGCL-NC or MEM
only (Virus), followed by CVB3 infection (MOI = 0.01). After 48 h, GFP-expressing cells were visualized by fluorescence microscopy. LM: light
microscopy, FM: fluorescence microscopy.
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supernatants were removed, and washed with PBS. Finally,
cells were overlaid with 2 ml of sterilized soft Bacto-agar/
MEM (2 × MEM:1.5% Bacto-agar = 1:1). The cells were
incubated at 37°C for 72 h, fixed with Carnoy’s fixative for
30 min and then stained with 1% crystal violet. The pla-
ques were counted and the viral pfu/ml was calculated
[20]. Each sample was tested in triplicate.
Statistics
All statistical analyses were performed using the SPSS
11.5 computer software program. Survival was analyzed
using Log-rank (Mantel-Cox) method. The significance
of variability among the experimental groups was deter-
mined by Mann–Whitney U test. All differences were
considered statistically significant at P < 0.05.
Results
Construction of recombinant plasmid and lentivirus
expressing shRNA targeting CVB3
In this study, recombinant plasmid expressing the
shRNA targeting 2B sequence was cloned into pGCSIL-
GFP and named pGCL-2B. This plasmid was used to
pack the infectious lentivirus particles by co-transfection
of 293T cells with other packaging plasmids. The lenti-
virus was named Lenti-2B and its titer was determined
by fluorescent microscopy. The titer of the recombinant
lentiviruses was approximately 2 × 109 TU/ml.
Inhibition of CVB3 replication in HeLa cells
To evaluate the transfection efficacy of pGCL-2B, HeLa
cells were transfected with pGCL-2B at a series of doses
and the GFP-expressing cells were visualized through
fluorescence microscopy after 24 h. The transfection rate
of pGCL-2B was determined by the percent of the area
of GFP-expressing cells versus that of whole HeLa cells
in one field calculated using Anymicro DSS™ digital
shoot system (Beijing Yutianshijiweiye Technology De-
velopment Co. Ltd., China). Figure 1A shows that
1.25 μg/well was the lowest dose of pGCL-2B to reach
about 60% of cells expressing GFP and was less toxic to
the cells. Higher the dose of plasmid used, more vacu-
olar change occurred in the cells. When HeLa cells were
Figure 2 Evaluation of the antiviral effects of Lenti-2B in HeLa cells. A HeLa cells were transduced with Lenti-2B at 1, 10, 100 TU/ml,
respectively, or Lenti-NC or MEM only (V), followed by CVB3 infection (MOI = 0.01). The viral titers were measured at 48 h p.i. using supernatants
of cell cultures by plaque-forming analysis and the results of three independent experiments are expressed as mean ± standard deviation.
Significant differences between Lenti-2B treated (white bars) and Lenti-NC treated samples (striped bars) are indicated (*: P< 0.05) B HeLa cells
were transduced with Lenti-2B (10 TU/well) or Lenti-NC or MEM only (Virus), followed by CVB3 infection (MOI = 0.01). After 48 h, GFP-expressing
cells were visualized by fluorescence microscopy. LM: light microscopy, FM: fluorescence microscopy.
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transfected with pGCL-2B of 6.25 μg/well, the cells died
after 24 h. Subsequently, pGCL-2B of 1.25 μg/well was
used to transfect HeLa cells, and GFP expressions
detected at different time. After 48 h, GFP expression
rate reached to the peak (Figure 1B). The transfection
rate of control plasmid was similar to that of pGCL-2B.
We also studied its antiviral efficacy as a function of
time and dose in HeLa cells. Compared to the viral titer
of pGCL-NC, an approximate 96% decrease in viral titer
was detected in these cultures treated with pGCL-2B
(1.25 μg/well) at 48 h post challenge. This protective ef-
fect was reduced after 60 h and 72 h (Figure 1C). Deter-
mination of CVB3 titers 48 h after infection showed a
strong antiviral effect of the pGCL-2B transfection with
titers reduced 95.83% at the plasmid dose of 1.25 μg/well
and 96.46% at the plasmid dose of 1.75 μg/well
(Figure 1D). Expectedly, HeLa cells pre-treated with a
dose of 1.25 μg/well of pGCL-2B were efficiently pro-
tected against CVB3-induced cell lysis at 48 h after
infection, while strong CPE occurred in other two
groups (Figure 1E).
To evaluate the efficacy of Lenti-2B on coxsackieviral
replication, Lenti-2B (1, 10, 100 TU/cell) or Lenti-NC
were used to transduce HeLa cells respectively. After
48 h, cells were infected with CVB3 (MOI = 0.01), and
then the culture supernatants were collected to deter-
mine the CVB3 titers by viral plaque analysis at 48 h
post challenge. Lenti-2B at a dose of 10 TU/cell or
100 TU/cell achieved an approximately 84% and 90%,
respectively, reduction of CVB3 titer compared with
that of control cells treated with Lenti-NC. The anti-
viral effect was almost absent at the dose of 1 TU/cell
because of the low transduction efficacy of the lenti-
virus (Figure 2A). Lenti-2B also exhibited the protect-
ive effect against CPE (Figure 2B). These results
indicate that recombinant plasmid and lentivirus
expressing shRNA-2B are highly efficient antiviral
agents in vitro.
Figure 3 Evaluation of the antiviral effects of shRNA-2B on
survival rate. BALB/c mice (n = 10) were injected with plasmid
(40 μg/mouse) or lentivirus (1 × 108 TU/mouse) through a tail vein,
24 h, post injection, 8 × 103 pfu/mouse of CVB3 was used as the
challenge.
Figure 4 Antiviral effects of Lenti-2B on the viral titers in the
hearts (A) and pancreases (B) of mice infected with CVB3. BALB/
c mice were pretreated with lentiviruses expressing shRNAs under
the condition described in the legend to Figure 3, and euthanized
at days, 3, 5 and 7 post infection with CVB3 (n = 5). The heart and
pancreas tissues were weighted and made a 0.2% (w/v)
homogenate in 0.5 ml MEM, followed by the determination of the
viral titers. Histogram represents average values of experiments
performed with samples obtained from five different mice. Error bars
represent mean ± standard deviation. *P<0.01.
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Inhibition of CVB3 replication in coxsackievirus-induced
myocarditis model
To reveal the effect of shRNA-2B on survival, virus rep-
lication, and tissue damage, pGCL-2B (20 μg/mouse,
30 μg/mouse or 40 μg/mouse) or Lenti-2B (1 × 107 TU/
mouse, 5 × 107 TU/mouse or 1 × 108 TU/mouse) was
injected into mice before infection with CVB3 virus. The
control vector pGCL-NC or Lenti-NC was applied in
the same way. Transfection of pGCL-NC or Lenti-NC
had no effect on survival compared with the infected but
non-treated animals. All mice died in 9 days after
infected with CVB3. In contrast, in the group infected
with 1 × 108 TU/mouse Lenti-2B, 50% mice were still
alive at day 9 and 40% mice lived at 30 days after chal-
lenge with CVB3 (Figure 3A). The pGCL-2B group
(40 μg/mouse) also showed a higher survival rate than
that of the pGCL-NC control group (30% vs. 0 survival
rate, P< 0.01) at day 9 post CVB3 infection (Figure 3B).
However, transfection of pGCL-2B or Lenti-2B with lower
doses had no difference on survival between treated
group and control group. Both pGCL-2B and Lenti-2B
improved significantly the life span of mice, suggesting
that shRNA-2B could be the potential agent to reduce the
mortality caused by viral myocarditis.
To further determine the potency of Lenti-2B, mice
were euthanized to directly compare the tissue virus
titers by plaque-forming assay at days 3, 5 and 7 post
CVB3 infection. The virus titers in the hearts and pan-
creases of mice infected with Lenti-2B were approxi-
mately 4-log10 lower than those in the control group
(P < 0.01 versus Lenti-NC group for both organs, n = 5 in
each group) (Figure 4). Virus titers were 1-log10 lower in
the heart and 2-log10 lower in the pancreas of mice that
received pGCL-2B than that in the respective control
mice (Figure 5). Furthermore, the virus titer was 103-fold
lower in the heart of Lenti-2B group than that of pGCL-
2B group, suggesting that lentivirus vector expressed
shRNA-2B more effectively than plasmid in vivo
(P < 0.01).
To confirm the protect effect of Lenti-2B on the hearts
and pancreases of CVB3 infected mice, hematoxylin-
eosin staining was used to detect inflammation and
immunohistochemistry staining was used to detect the
distribution of CVB3 viruses or GFP expression in the
organs. No, or only slight, myocardial inflammation and
CVB3 infection were revealed in the Lenti-2B group;
however, there were large extent of necrosis, calcification
and serious virus infection in the Lenti-NC group and
non-shRNA-treated group (Figure 6).
Discussion
Coxsackievirus infection can injure cell directly and
damage various tissues, leading to viral heart disease [2],
pancreatitis [3], or meningitis [4]. At present, there is no
specific antiviral therapy available [21]. RNAi-based anti-
viral therapy has potential to degrade viral RNA and
promote viral clearance [22]. In previous publications,
RNAi was applied to inhibit coxsackievirus replication
by siRNAs targeting viral 2A [23,24], 3D [25], and VP1
[15,25]. These synthetic siRNAs were tansfected into
mammalian cells or delivered into mice via the tail vein
by high-volume injections and protected cells or organs
from virus-mediated injury. However, the degradation of
siRNAs by intracellular nucleases and the method of de-
livery limited the effect in vivo. To overcome some limita-
tions of siRNAs in antiviral applications, adeno-associated
virus-delivered shRNA directed at the RNA polymerase
of CVB3 was reported to significantly attenuate the car-
diac dysfunction [26] and lentivirus-delivered shRNA
against 2C was reported to improve survival rate in an
animal mode [27]. It was suggested that shRNA viral vec-
tor could be used effectively to prevent coxsackievirus
replication in mice.
Figure 5 Antiviral effects of pGCL-2B on the viral titers in the
hearts (A) and pancreases (B) of mice infected with CVB3. BALB/
c mice were pretreated with plasmid expressing shRNAs under the
condition described in the legend to Figure 3, and euthanized at
days 3, 5 and 7 after infection with CVB3 (n = 5). The heart and
pancreas tissues were weighted and made a 0.2% (w/v)
homogenate in 0.5 ml MEM, followed by the determination of the
viral titers. Histogram represents average values of experiments
performed with samples obtained from five different mice. Error bars
represent mean ± standard deviation. *P<0.01.
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In this study, RNA interference was employed to tar-
get the CVB3 protein 2B region (3753-3771), which is a
highly conserved region in most enteroviruses and there-
fore is an attractive therapeutic target. Among twelve
siRNAs we tested, siRNA-2B was proved most highly ef-
ficient in the inhibition of viral replication in HeLa cells.
In subsequent animal experiments, lentivirus-delivered
shRNA-2B was shown to improve the survival rate of
40% at 30 days after challenge. Furthermore, the viral
titers in the mouse hearts and pancreas of the Lenti-2B
group were significantly reduced compared with those of
the control group. The biopsy of hearts and pancreas of
mice injected with Lenti-2B also showed less inflamma-
tion, suggesting that shRNA-2B effectively inhibits viral
replication and reduces the virus-induced myocarditis in
the animal model. This study indicated that shRNA-2B
can reduce CVB3 progeny production by cleavage of
viral genomic RNA, which results in the suppression of
viral particle assembly with intact CVB3 RNAs and ham-
pering of the whole translation process of the viral poly-
protein. On the other hand, it was reported that 2B
protein plays a major role in suppressing apoptotic host
cell response by manipulating intracellular Ca2+ homeo-
stasis and, thereby, in extending the life span of the host
cell [28]. However, this RNAi by shRNA-2B may en-
hance host cell death and subsequently limit CVB3 repli-
cation. Therefore, shRNA-2B inhibits CVB3 replication
not only directly through RNAi but also indirectly
through enhancing host cell death.
In recent years, many studies have reported successful
inhibition of viral replication in cultured cells or in
murine models using transient transfection of synthetic
siRNA or plasmid expressing shRNA. However, the anti-
viral effect of RNAi depends on the delivery efficacy of
siRNA or shRNA. We evaluated the effect of shRNA-2B
expressed using both plasmid vector and lentiviral vec-
tor. The data presented here indicate that the viral titers
in HeLa cell supernatants were less in the pGCL-2B
group than in the Lenti-2B group. Inversely, the viral
titers in mouse heart and pancreas were decreased much
more in the Lenti-2B group than in the pGCL-2B group,
suggesting that the expression of shRNA-2B with viral
vector exhibited higher inhibitory efficiency on viral rep-
lication than with plasmid vector in vivo. Thus, lentiviral
vector is a promising viral vehicle for delivery of shRNAs
and shRNA-2B has great potential to be further devel-
oped into an effective therapeutics for the treatment of
coxsackievirus and other enterovirus infections.
Conclusions
shRNA-2B significantly reduced the virus titer of CVB3
in HeLa cells, also prolonged the mouse survival span,
attenuated the tissue damage and inhibited the viral pro-
duction in vivo compared with those of the shRNA-NC
treated control group, suggesting that shRNA-2B is a
potentially therapeutic agent for the treatment of enter-
viral diseases.
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Figure 6 Histology of myocardial inflammation (A) and pancreatic inflammation (B) at day 7 after CVB3 challenge. BALB/c mice were
injected with Lenti-2B (1 × 108 TU/mouse) through the tail vein, at 24 h post injection, 8 × 103 pfu/mouse of CVB3 was used as the challenge, and
then euthanized at day 7 post CVB3 infection. The four groups were injected with Lenti-2B or Lenti-NC or MEM but infected with CVB3 (V) or
MEM only as normal control. Hematoxylin-eosin staining and immunohistochemical analysis of CVB3 or GFP were performed on the sections
prepared from the hearts. Untreated Control shows the control section was treated without the first antibody in IHC staining. Green arrow shows a
example of infiltration, red arrows show examples of necrosis and calcification, black arrows show examples of CVB3 infection, purple arrows show
examples of GFP-expressing. Magnification, 200×.
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